Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/108814
Title: Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial
Author: Kaasch, Achim J.
Fätkenheuer, Gerd
Prinz-Langenohl, Reinhild
Paulus, Ursula
Hellmich, Martin
Weiß, Verena
Jung, Norma
Rieg, Siegbert
Kern, Winfried V.
Seifert, Harald
Soriano Viladomiu, Alex
SABATO trial group
Keywords: Infeccions nosocomials
Staphylococcus aureus
Microbiologia sanitària
Contaminació microbiana
Nosocomial infections
Staphylococcus aureus
Sanitary microbiology
Microbial contamination
Issue Date: 9-Oct-2015
Publisher: BioMed Central
Abstract: Background Current guidelines recommend that patients with Staphylococcus aureus bloodstream infection (SAB) are treated with long courses of intravenous antimicrobial therapy. This serves to avoid SAB-related complications such as relapses, local extension and distant metastatic foci. However, in certain clinical scenarios, the incidence of SAB-related complications is low. Patients with a low-risk for complications may thus benefit from an early switch to oral medication through earlier discharge and fewer complications of intravenous therapy. The major objective for the SABATO trial is to demonstrate that in patients with low-risk SAB a switch from intravenous to oral antimicrobial therapy (oral switch therapy, OST) is non-inferior to a conventional course of intravenous therapy (intravenous standard therapy, IST). Methods/Design The trial is designed as randomized, parallel-group, observer-blinded, clinical non-inferiority trial. The primary endpoint is the occurrence of a SAB-related complication (relapsing SAB, deep-seated infection, and attributable mortality) within 90 days. Secondary endpoints are the length of hospital stay; 14-day, 30-day, and 90-day mortality; and complications of intravenous therapy. Patients with SAB who have received 5 to 7 full days of adequate intravenous antimicrobial therapy are eligible. Main exclusion criteria are polymicrobial bloodstream infection, signs and symptoms of complicated SAB (deep-seated infection, hematogenous dissemination, septic shock, and prolonged bacteremia), the presence of a non-removable foreign body, and severe comorbidity. Patients will receive either OST or IST with a protocol-approved antimicrobial and are followed up for 90 days. Four hundred thirty patients will be randomized 1:1 in two study arms. Efficacy regarding incidence of SAB-related complications is tested sequentially with a non-inferiority margin of 10 and 5 percentage points. Discussion The SABATO trial assesses whether early oral switch therapy is safe and effective for patients with low-risk SAB. Regardless of the result, this pragmatic trial will strongly influence the standard of care in SAB. Trial registration ClinicalTrials.gov NCT01792804 registered 13 February 2013; German Clinical trials register DRKS00004741 registered 4 October 2013, EudraCT 2013-000577-77. First patient randomized on 20 December 2013.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s13063-015-0973-x
It is part of: Trials, 2015, vol. 16, num. 450
Related resource: https://doi.org/10.1186/s13063-015-0973-x
URI: http://hdl.handle.net/2445/108814
ISSN: 1745-6215
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
669566.pdf1.36 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons